LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Eliza Vakana(Eli Lilly (United States)), Louis F. Stancato(Eli Lilly (United States))
Cited by 68
Related Papers
A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells
|Cell Death and Differentiation|2012|65
A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology
|PLoS ONE|2015|18
Regulatory Effects of Sestrin 3 (SESN3) in BCR-ABL Expressing Cells
|PLoS ONE|2013|17